For U.S. Healthcare Professionals

Start with OPSUMIT® (macitentan) to reduce the risks of disease progression and hospitalization for PAH1

In the treatment of pulmonary arterial hypertension (PAH, WHO Group I)

OPSUMIT® campaign
Contact your
Local MSL
 Request A Medical Science
Liaison (MSL)
Contact your
Local MSL
 Request A Medical Science
Liaison (MSL)

Individual patient experience may vary. OPSUMIT® has a 9-year long-term safety, tolerability, and survival open-label extension study in patients with PAH.1

Learn more about OPSUMIT® clinical data

View overall results from the SERAPHIN pivotal trial

SEE THE DATA
Explore an additional OPSUMIT® analysis

Read about the REPAIR study

SEE THE DATA
See SERAPHIN PAH-related hospitalization data

View PAH-related hospitalization data

SEE THE DATA
Need downloadable resources?

View our library of downloadable materials for HCPs and patients

GET RESOURCES
Explore SERAPHIN PAH-CTD subgroup data

View PAH-CTD subgroup post hoc analyses

SEE THE DATA
Watch patient and HCP perspectives on PAH

Access the video library

VIEW VIDEOS

BACK TO TOP

HCP=healthcare professional; PAH=pulmonary arterial hypertension; PAH-CTD=PAH associated with connective tissue disease; REPAIR=Right vEntricular remodeling in Pulmonary ArterIal hypeRtension; SERAPHIN=Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve CliNical Outcome; WHO=World Health Organization.
Reference: 1. Souza R, Delcroix M, Galié N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39(9):4374-4390

To report suspected adverse reactions, contact Janssen at 1-800-JANSSEN (1-800-526-7736), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Contact Medical Information

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
©2023 Actelion Pharmaceuticals US, Inc. 
cp-136843v11 10/23

EXPAND +

+ +